Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina Inc (NASDAQ: ILMN) says the European Union will issue a list of objections tomorrow over the Company's $8B takeover of GRAIL, Bloomberg reports. Related Link:   EC Adopts Interim Measure, Tells Grail To Work On Alternatives To Illumina Deal.

Europe To Layout Objections to Illumina-Grail Deal: Bloomberg

SAN DIEGO, Nov. 16, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Genetic Alliance today announced the creation of the iHope™ Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by genetic disease. At least half of iHope Genetic Health's efforts will be focused on areas of the world in need outside the US, with more than one-third of Illumina's support being dedicated to patients in Africa.

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

Illumina Inc (NASDAQ: ILMN) reported Q3 revenues of $1.11 billion, +40% Y/Y, beating the consensus of $1.04 billion. Consolidated Product revenues were $978 million, while Service and other revenues were $130 million.

Illumina Clocks 40% Growth In Q3; Earnings Beat Expectations

Illumina, Inc. (ILMN) CEO Francis Desouza Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2021, which include the consolidated financial results of GRAIL. Third quarter consolidated results: Revenue of $1,108 million, a 40% increase compared to the prior year period GAAP net income for the quarter of $317 million, or $2.08 per diluted share, which included a $900 million gain from our previously held investment in GRAIL and $654 million in day one compensation expense related to the GRAIL acquisition.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced that its world-class sequencing and bioinformatics solutions are being used by HostSeq, part of the Canadian COVID-19 Genomics Network (CanCOGeN), to identify biomarkers that can help predict potential risk of serious disease and support the development of novel therapeutics to combat COVID-19. By sequencing the genomes of up to 10,000 patients diagnosed or affected by COVID-19 throughout Canada, the findings from this program will help researchers and the medical community better understand the role of human genetics in COVID-19 susceptibility.

Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative

The European Commission (EC) told Grail to "actively work" on alternatives to its acquisition by Illumina Inc (NASDAQ: ILMN) if the takeover is ultimately blocked in the internal market. Related Link:   Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process.

EC Adopts Interim Measure, Tells Grail To Work On Alternatives To Illumina Deal

The European Commission said on Friday it had taken interim measures following life science company Illumina's early acquisition of cancer detection test maker Grail Inc, including an order that Grail be kept separate.

EU orders Illumina to keep Grail a separate company

SAN DIEGO, Oct. 27, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced an agreement with Israel's Ministry of Health (MoH) for a pilot program to implement the use of whole-genome sequencing (WGS) in critically-ill infants suspected of having a genetic disorder in neonatal intensive care units (NICU). The program, led by the Genetics Institute (Tel-Aviv Sourasky Medical Center), will evaluate the use of WGS in routine care as an effective first-tier diagnostic tool to enable faster identification of disease-causing genetic abnormalities in infants, aiding their clinical care and management.

Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease

JD.com

Stoneridge

TPI Composites

Steer clear of toxic stocks like SRI, ILMN, TPIC and JD to safeguard your portfolio from losses.

Let Go of These 4 Toxic Stocks Right Away

SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will host its first Environment, Social and Corporate Governance (ESG) focused investor event at 11:00 am Pacific Time (2:00 pm Eastern Time), Tuesday, November 16, 2021. Francis deSouza, President and Chief Executive Officer, Sam Samad, Chief Financial Officer, and Sharon Vidal, Global Lead, Corporate Social Responsibility, will be joined by Maggie Lake, journalist and ESG communication specialist, for a presentation and fireside chat for investors, analysts, and other interested parties regarding Illumina's ESG strategy and action plans.

Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021

Fiserv

Mastercard

Fundamental investors shouldn't ignore charts completely. Here, we look at a few opportunities as signaled by their 200-day moving average (MA).

"Below-Average" Stocks With Above-Average Potential

SAN DIEGO, Oct. 14, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, effective immediately. GRAIL currently operates as a separate and independent unit of Illumina.

Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2021 following the close of market on Thursday, November 4, 2021.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's bid for Grail Inc after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday.

EU antitrust regulators resume Illumina, Grail probe, decision due by Feb. 4

The company's merger with GRAIL concerned investors.

Why Shares of Ilumina Slumped 11.3% in September

Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.

Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced the creation of Illumina Colombia S.A.S.

Illumina Expands Presence in Latin America

SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) scientists, together with investigators from five children's hospital across the US, have co-authored a study published today in JAMA Pediatrics  reporting findings from the NICUSeq Randomized Time-Delayed Trial.

Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants

U.S. life sciences company Illumina said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clearance of the deal.

Illumina says it had expected EU hold order on Grail

EU antitrust regulators on Monday announced interim measures against U.S. life sciences company Illumina for for closing its $8 billion cash-and-stock takeover of cancer detection test maker Grail deal before gaining approval.

EU regulators impose interim measures against Illumina in Grail deal

SAN FRANCISCO--(BUSINESS WIRE)--Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, including the Ireland Strategic Investment Fund (ISIF). The fund will sup

Illumina Ventures Closes $325 Million Fund

DexCom

Teladoc

Veeva Systems

The merging of healthcare and technology is changing how we care for our bodies. It's also creating investment opportunities, such as these five medical technology stocks.

5 Medtech Stocks to Seize Major Growth

SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.

News for Illumina Stock (ILMN)